Hélène Le Buanec, Valérie Schiavon, Marine Merandet, Alexandre How-Kit, Hongshuo Song, David Bergerat, Céline Fombellida-Lopez, Armand Bensussan, Jean-David Bouaziz, Arsène Burny, Gilles Darcis, Mohammad M Sajadi, Shyamasundaran Kottilil, Daniel Zagury, Robert C Gallo
BACKGROUND: Among people living with HIV, elite controllers (ECs) maintain an undetectable viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to marked improvement, including in immune parameters, but unlike ECs, non-EC patients still require ongoing treatment and experience co-morbidities. In-depth, comprehensive immune analyses comparing EC and treated non-EC patients may reveal subtle, consistent differences. This comparison could clarify whether elevated circulating interferon-alpha (IFNα) promotes widespread immune cell alterations and persists post-therapy, furthering understanding of why non-EC patients continue to need treatment...
March 19, 2024: Commun Med (Lond)